Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil.
Meta-analysis
Multiple sclerosis
Prevalence
Secondary progressive multiple sclerosis
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
received:
14
06
2021
accepted:
01
07
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
20
8
2022
Statut:
epublish
Résumé
Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS), which is a chronic neurological disease, characterised by inflammation of the central nervous system. Most of MS patients eventually progress to SPMS. This study estimates the prevalence of SPMS in the United States of America, Europe, Canada, Australia, and Brazil. A systematic literature search of the Medline and Embase databases was performed using the OVID™ SP platform to identify MS epidemiological studies published in English from database inception to September 22, 2020. Studies reporting the prevalence of MS and proportion of SPMS patients in the included population were selected. The pooled prevalence of SPMS was calculated based on the proportion of SPMS patients. The Loney quality assessment checklist was used for quality grading. A meta-analysis of the proportions was conducted in RStudio. A total of 4754 articles were retrieved, and prevalence was calculated from 97 relevant studies. Overall, 86 medium- and high-quality studies were included in the meta-analysis. Most studies were conducted in European countries (84 studies). The estimated pooled prevalence of SPMS was 22.42 (99% confidence interval: 18.30, 26.95)/100,000. The prevalence of SPMS was more in the North European countries, highest in Sweden and lowest in Brazil. A decline in SPMS prevalence was observed since the availability of oral disease-modifying therapies. We also observed a regional variation of higher SPMS prevalence in urban areas compared with rural areas. High variability was observed in the estimated SPMS prevalence, and the quality of the studies conducted. The influence of latitude and other factors known to affect overall MS prevalence did not fully explain the wide range of inter-country and intra-country variability identified in the results.
Sections du résumé
BACKGROUND
BACKGROUND
Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS), which is a chronic neurological disease, characterised by inflammation of the central nervous system. Most of MS patients eventually progress to SPMS. This study estimates the prevalence of SPMS in the United States of America, Europe, Canada, Australia, and Brazil.
METHODS
METHODS
A systematic literature search of the Medline and Embase databases was performed using the OVID™ SP platform to identify MS epidemiological studies published in English from database inception to September 22, 2020. Studies reporting the prevalence of MS and proportion of SPMS patients in the included population were selected. The pooled prevalence of SPMS was calculated based on the proportion of SPMS patients. The Loney quality assessment checklist was used for quality grading. A meta-analysis of the proportions was conducted in RStudio.
RESULTS
RESULTS
A total of 4754 articles were retrieved, and prevalence was calculated from 97 relevant studies. Overall, 86 medium- and high-quality studies were included in the meta-analysis. Most studies were conducted in European countries (84 studies). The estimated pooled prevalence of SPMS was 22.42 (99% confidence interval: 18.30, 26.95)/100,000. The prevalence of SPMS was more in the North European countries, highest in Sweden and lowest in Brazil. A decline in SPMS prevalence was observed since the availability of oral disease-modifying therapies. We also observed a regional variation of higher SPMS prevalence in urban areas compared with rural areas.
CONCLUSION
CONCLUSIONS
High variability was observed in the estimated SPMS prevalence, and the quality of the studies conducted. The influence of latitude and other factors known to affect overall MS prevalence did not fully explain the wide range of inter-country and intra-country variability identified in the results.
Identifiants
pubmed: 35978300
doi: 10.1186/s12883-022-02820-0
pii: 10.1186/s12883-022-02820-0
pmc: PMC9382820
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
301Informations de copyright
© 2022. The Author(s).
Références
Neuroepidemiology. 1998;17(5):258-64
pubmed: 9705585
Mult Scler Relat Disord. 2019 Aug;33:78-81
pubmed: 31170564
Neuroepidemiology. 2008;30(3):167-73
pubmed: 18382116
Clin Neurol Neurosurg. 2007 Nov;109(9):779-83
pubmed: 17766036
J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):719-24
pubmed: 22577232
Can J Neurol Sci. 1992 Feb;19(1):72-5
pubmed: 1562911
Neuroepidemiology. 2019;53(1-2):108-114
pubmed: 31170722
Neuroepidemiology. 2001 May;20(2):129-33
pubmed: 11359081
J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):572-6
pubmed: 15026499
BMC Neurol. 2020 May 19;20(1):195
pubmed: 32429866
Acta Neurol Scand. 2020 Sep;142(3):267-274
pubmed: 32392359
Clin Neurol Neurosurg. 2013 Sep;115(9):1806-8
pubmed: 23727367
Acta Neurol Scand. 2015 Dec;132(6):381-8
pubmed: 25891133
Neuroepidemiology. 2016;46(2):88-95
pubmed: 26731675
Mult Scler. 2008 Aug;14(7):880-6
pubmed: 18573832
J Neurol Sci. 2009 Nov 15;286(1-2):14-7
pubmed: 19691994
Mult Scler. 2010 Dec;16(12):1432-6
pubmed: 20834041
Eur J Neurol. 2008 Jan;15(1):73-6
pubmed: 18042236
Neurol Sci. 2018 Jul;39(7):1231-1236
pubmed: 29671168
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
J Neurol Neurosurg Psychiatry. 1995 May;58(5):577-81
pubmed: 7745405
Neuroepidemiology. 2011;37(3-4):231-5
pubmed: 22133733
Neuroepidemiology. 2008;30(3):147-51
pubmed: 18382113
Neurol Sci. 2020 May;41(5):1089-1095
pubmed: 31872352
Turk J Med Sci. 2019 Feb 11;49(1):288-294
pubmed: 30761870
Neuroepidemiology. 1995;14(1):7-13
pubmed: 7898604
J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):71-6
pubmed: 7608713
J Neurol. 2006 Jul;253(7):914-8
pubmed: 16502218
Eur J Neurol. 2013 Apr;20(4):697-703
pubmed: 23279712
Acta Neurol Scand. 2004 Jun;109(6):378-84
pubmed: 15147459
Neuroepidemiology. 2011;37(2):102-6
pubmed: 21921643
J Neurol. 2002 Oct;249(10):1378-81
pubmed: 12382152
Med Arch. 2014 Jun;68(3):178-81
pubmed: 25568528
Neuropsychiatr Dis Treat. 2017 May 18;13:1349-1357
pubmed: 28572730
J Neurol Neurosurg Psychiatry. 1998 May;64(5):605-10
pubmed: 9598675
Acta Neurol Scand. 2011 Oct;124(4):250-7
pubmed: 21143594
Acta Neurol Scand. 1998 Oct;98(4):238-42
pubmed: 9808272
Chronic Dis Can. 1998;19(4):170-6
pubmed: 10029513
Am J Epidemiol. 2009 Aug 1;170(3):289-96
pubmed: 19546151
Arq Neuropsiquiatr. 2015 Sep;73(9):741-5
pubmed: 26352490
Neuroepidemiology. 1999;18(4):218-22
pubmed: 10364723
Arq Neuropsiquiatr. 2012 Feb;70(2):102-7
pubmed: 22311213
Arq Neuropsiquiatr. 2019 May 01;77(5):352-356
pubmed: 31189000
J Neurol. 1997 Mar;244(3):182-5
pubmed: 9050959
J Neurol Sci. 2006 Sep 25;247(2):169-72
pubmed: 16806273
Acta Neurol Scand. 2001 Oct;104(4):208-13
pubmed: 11589649
Neurology. 2001 Jan 9;56(1):62-6
pubmed: 11148237
Arch Neurol. 1996 Aug;53(8):793-8
pubmed: 8759986
Stat Med. 2002 Sep 30;21(18):2641-52
pubmed: 12228882
Neurology. 2014 Jul 15;83(3):278-86
pubmed: 24871874
Acta Neurol Scand. 2014 Nov;130(5):277-82
pubmed: 24611546
J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):317-22
pubmed: 21248317
Neurology. 2005 Oct 25;65(8):1259-63
pubmed: 16247054
J Neurol. 2002 Mar;249(3):260-5
pubmed: 11993523
Mult Scler. 2008 Apr;14(3):325-9
pubmed: 18208882
Mult Scler. 2009 Nov;15(11):1253-62
pubmed: 19805442
Eur Neurol. 2003;49(1):8-12
pubmed: 12464712
J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):349-52
pubmed: 10675219
Acta Neurol Scand. 2015 Aug;132(2):111-7
pubmed: 25649860
Neurology. 1998 Feb;50(2):423-8
pubmed: 9484366
J Neurol Sci. 2003 Dec 15;216(1):89-93
pubmed: 14607307
J Neurol. 2005 Apr;252(4):436-40
pubmed: 15726261
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Neuroepidemiology. 2018;51(3-4):158-165
pubmed: 30130759
Acta Neurol Scand. 2020 May;141(5):431-437
pubmed: 31954069
Neurology. 1993 Sep;43(9):1760-3
pubmed: 8414027
Acta Neurol Scand. 1994 Dec;90(6):377-81
pubmed: 7892754
Acta Neurol Scand. 2019 Nov;140(5):303-311
pubmed: 31271648
Mult Scler Relat Disord. 2020 Sep;44:102254
pubmed: 32562908
J Neurol Sci. 2003 Sep 15;213(1-2):1-6
pubmed: 12873746
J Neurol. 2007 Dec;254(12):1642-8
pubmed: 18008026
BMC Neurol. 2016 Aug 11;16(1):134
pubmed: 27516084
Mult Scler. 2017 Jul;23(8):1063-1071
pubmed: 27682228
Acta Neurol Scand. 1988 Jul;78(1):10-5
pubmed: 3176876
Rev Neurol (Paris). 2016 Jan;172(1):3-13
pubmed: 26718593
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):56-60
pubmed: 14707308
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Acta Neurol Scand. 1985 Sep;72(3):321-7
pubmed: 4061052
Mult Scler Relat Disord. 2018 Apr;21:51-55
pubmed: 29455075
Arq Neuropsiquiatr. 2011 Apr;69(2A):184-7
pubmed: 21537557
Acta Neurol Scand. 1989 Jul;80(1):46-50
pubmed: 2782041
J Neurol. 1999 Mar;246(3):170-4
pubmed: 10323313
J Med Econ. 2020 Feb;23(2):156-165
pubmed: 31617776
Noro Psikiyatr Ars. 2017 Mar;54(1):11-14
pubmed: 28566952
Mult Scler. 2020 Dec;26(14):1816-1821
pubmed: 33174475
Can J Neurol Sci. 2005 Feb;32(1):37-42
pubmed: 15825544
Eur Neurol. 2001;46(4):206-9
pubmed: 11721128
Acta Neurol Scand. 1998 May;97(5):315-9
pubmed: 9613561
Neuroepidemiology. 2006;27(1):17-21
pubmed: 16770082
Neuroepidemiology. 2005;24(1-2):70-5
pubmed: 15459512
Neurol Neurochir Pol. 2017 Jan - Feb;51(1):82-85
pubmed: 27889289
Rom J Neurol Psychiatry. 1994 Apr-Jun;32(2):115-22
pubmed: 8075021
Mult Scler Relat Disord. 2018 May;22:1-7
pubmed: 29501849
Neuroepidemiology. 2007;28(1):28-32
pubmed: 17164567
Mult Scler Relat Disord. 2016 Sep;9:31-5
pubmed: 27645340
BMC Health Serv Res. 2014 Sep 10;14:381
pubmed: 25209585
Mult Scler. 2011 Mar;17(3):273-80
pubmed: 21071466
Neurol Res Int. 2015;2015:895163
pubmed: 25642348
Brain Behav. 2020 May;10(5):e01598
pubmed: 32196981
Medicine (Baltimore). 2018 Oct;97(42):e12856
pubmed: 30334992
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
Coll Antropol. 2010 Apr;34 Suppl 2:141-4
pubmed: 21305733
Coll Antropol. 2010 Mar;34 Suppl 1:189-93
pubmed: 20402317
Neurol Clin. 2016 Nov;34(4):919-939
pubmed: 27720001